| DESCRIPTION | - BOXUS et al., J Virol, (20070000), vol. 81, pages 6879 - 89 | - |
| DESCRIPTION | - EL OUAHABI et al., FEBSLetts, (19960000), vol. 380, pages 108 - 12 | - |
| DESCRIPTION | - GIULIANI et al., Proc Natl Acad Sci USA, (20060000), vol. 1, 2, 3, no. 29, pages 10834 - 9 | - |
| DESCRIPTION | - Handbook of Experimental Immunology, Blackwell Scientific Publications, (19860000), vol. 1-4 | - |
| DESCRIPTION | - HEYES et al., J Controlled Release, (20050000), vol. 107, pages 276 - 87 | - |
| DESCRIPTION | - HOEKSTRA et al., Biochimica et Biophysica Acta, (20040000), vol. 1660, pages 41 - 52 | - |
| DESCRIPTION | - JEFFS et al., Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372 | - |
| DESCRIPTION | - JOHANNING et al., Nucleic Acids Res, (19950000), vol. 23, pages 1495 - 1501 | - |
| DESCRIPTION | - MAURER et al., Biophysical Journal, (20010000), vol. 80, pages 2310 - 2326 | - |
| DESCRIPTION | - "Microspheres, microcapsules & liposomes", Functional Polymer Colloids and Microparticles, Citus Books, (20020000), vol. 4 | - |
| DESCRIPTION | - PERRI et al., J Virol, (20030000), vol. 77, pages 10394 - 10403 | - |
| DESCRIPTION | - ROMBERG et al., Pharmaceutical Research, (20080000), vol. 25, pages 55 - 71 | - |
| DESCRIPTION | - TAYLOR et al., Vaccine, (20050000), vol. 23, pages 1242 - 50 | - |
| DESCRIPTION | - YONEYAMAFUJITA, Cytokine & Growth Factor Reviews, (20070000), vol. 18, pages 545 - 51 | - |
| OPPOSITION | - Anonymous, "Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, pages 1 - 706, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS , URL: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty, XP093243681 | - |
| OPPOSITION | - Anonymous, "m7G(5')ppp(5')G RNA Cap Structure Analog", The New England Biolabs, (20100401), pages 1 - 2, XP093024994 | - |
| OPPOSITION | - Anonymous, "mMESSAGE mMACHINE ® Kit High Yield Capped RNA Transcription Kit", User Guide mMESSAGE mMACHINE ® Kit, Ambion by life technologies, pages 1 - 36, User Guide mMESSAGE mMACHINE ® Kit, URL: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/cms_055516.pdf, XP093243409 | - |
| OPPOSITION | - Anonymous, "mScript™ mRNA Production System", Epicentre Biotechnologies, (20060101), page 1, XP093031630 | - |
| OPPOSITION | - Anonymous, "Overview of mRNA vaccine development", Pfizer Overview, Pfizer, pages 1 - 1, Pfizer Overview, XP093244078 | - |
| OPPOSITION | - Anonymous, "ScriptCap™ 2'-O-Methyltransferase", In Vitro Transcription and RNA | In Vitro Transcription Kits, EPICENTRE® Biotechnologies, pages 1 - 1, In Vitro Transcription and RNA | In Vitro Transcription Kits, URL: https://web.archive.org/web/20061116025912/http://www.epibio.com/item.asp?ID=500&CatID=12&SubCatID=26, XP093243325 | - |
| OPPOSITION | - Anonymous, "ScriptCap™ m7G Capping System ", Epicentre Biotechnologies, (20061101), pages 1 - 2, XP093045334 | - |
| OPPOSITION | - Anonymous, "ScriptCap™ m7G Capping System", In vitro Transcription - In Vitro Transcription - ScriptCap™ m7G Capping System, Cambio - Excellence in Molecular Biology, pages 1 - 3, In vitro Transcription - In Vitro Transcription - ScriptCap™ m7G Capping System, URL: https://www.cambio.co.uk/0/443/21/products/scriptcap-m7g-capping-system/#tab2, XP093243337 | - |
| OPPOSITION | - Anonymous, "Spikevax 0.2 mg/mL dispersion for injection Spikevax 0.1 mg/mL dispersion for injection Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, EUROPEAN MEDICINES AGENCY SCIENCE, pages 1 - 270, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/spikevax-epar-product-information_en.pdf, XP093243692 | - |
| OPPOSITION | - Anonymous, "Spikevax1 (COVID-19 mRNA Vaccine (nucleoside modified)), EMA/765306/2022 EMEA/H/C/005791", EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH, (20220101), pages 1 - 5, XP093045427 | - |
| OPPOSITION | - Anonymous, "Transcription in vitro", Promega Protocols and Applications Guide, 3rd ed., USA, Promega Corp., (19960101), pages 115 - 122, ISBN 978-1-882274-57-4, XP093243625 | - |
| OPPOSITION | - Anonymous, "TriLink - About us", Website TriLink, TriLink BioTechnologies, pages 1 - 3, Website TriLink, URL: https://www.trilinkbiotech.com/about-us, XP093243335 | - |
| OPPOSITION | - Anonymous, "Wayback machine - ScriptCap m7G Capping System", Epicentre Biotechnologies, (20061116), pages 1 - 2, Epicentre Biotechnologies, (20230314), XP093031527 | - |
| OPPOSITION | - Anonymous, "What is Cap-0 and Cap-1?", FAQs, New England Biolabs, pages 1 - 1, FAQs, URL: https://www.neb.com/en/faqs/2018/11/15/what-is-cap-0-and-cap-1, XP093243319 | - |
| OPPOSITION | - Anonymous, "Zika vaccine (mRNA-1325 and mRNA-1893)", Excerpt from Moderna's 2018 10-K, (20180101), pages 1 - 4, XP093045397 | - |
| OPPOSITION | - BANGS et al., "Mass Spectrometry of mRNA Cap 4 from Trypanosomatids Reveals Two Novel Nucleosides", J. Biol. Chem., (19920000), vol. 267, pages 9805 - 9815, XP000608118 | - |
| OPPOSITION | - Barbosa Christopher, "N:P RATIO CHARACTERIZATION", Research Report No. ACU-NC-0640, Acuitas Therapeutics Inc., Canada, Canada, pages 1 - 14, Research Report No. ACU-NC-0640 , URL: https://acuitastx.com/, XP093243647 | - |
| OPPOSITION | - CHUNG et al., "Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase", Proc. Natl. Acad. Sci USA, (19940000), vol. 91, pages 2372 - 2376, XP000600722 | - |
| OPPOSITION | - Dolgin Elie, "TRIAL SETTLES DEBATE OVER BEST DESIGN FOR MRNA IN COVID VACCINES", Nature, Springer Nature Limited, (20230119), pages 419 - 420, XP093045416 | - |
| OPPOSITION | - Hudson Paul, "Innovation to drive sustainable growth in Vaccines, Part 1", Vaccines Investor Event, Sanofi, (20230629), pages 1 - 118, XP093243392 | - |
| OPPOSITION | - IMMORDINO et al., "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", Intl. J. Nanomed., (20060000), vol. 1, pages 297 - 315, XP009145524 | - |
| OPPOSITION | - Immordino Maria Laura; Dosio Franco; Cattel Luigi, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD., AUCKLAND, NZ, AUCKLAND, NZ , (20060101), vol. 1, no. 3, ISSN 1176-9114, pages 297 - 315, XP009145524 | - |
| OPPOSITION | - Lowe Derek, "CureVac Comes Around", Science, (20230101), pages 1 - 3, XP093045422 | - |
| OPPOSITION | - MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY:PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305 | - |
| OPPOSITION | - Meis Judith E, Meis Ronald, "The New mscrip tTM mRNA Production System - Efficient mRNA Transcription, Capping and Tailing for the Highest Yields of Active Protein", EPICENTRE Biotechnolgies Forum, (20170101), vol. 14, no. 1, pages 1 - 3, XP093031513 | - |
| OPPOSITION | - PASCOLO STEVE, "Messenger RNA-based vaccines.", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20040801), vol. 4, no. 8, ISSN 1744-7682, pages 1285 - 1294, XP002764729 | - |
| OPPOSITION | - Rice Charles M, Et Al, "Production of Infectious RNA Transcripts from Sindbis Virus cDNA Clones: Mapping of Lethal Mutations, Rescue of a Temperature-Sensitive Marker, and In Vitro Mutagenesis To Generate Defined Mutants", Journal of Virology, (19870101), vol. 61, no. 12, pages 3809 - 3819, XP093031508 | - |
| OPPOSITION | - Shin Dongwon, Azizian Krist T, Henderson Jordana M, Hogrefe Richard I, Lebedev Alexandre, Houston Michael, Mccaffrey Anton P, "CleanCap ® Co-transcriptional Capping Streamlines mRNA Manufacturing", CleanCap ® Co-transcriptional Capping Streamlines mRNA Manufacturing, TriLink Biotechnologies, pages 1 - 1, CleanCap ® Co-transcriptional Capping Streamlines mRNA Manufacturing, URL: https://www.trilinkbiotech.com/media/contentmanager/content/mRNA_WVC2_1.pdf, XP093243330 | - |
| OPPOSITION | - VAN DEN BERG et al., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", J Control Release, (20100125), vol. 141, no. 2, pages 234 - 40, XP026815097 | - |
| OPPOSITION | - VAN DEN BERG et al., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", J. Contr. Release, vol. 141, no. 210, pages 234 - 240, XP026815097 | - |
| OPPOSITION | - Wong, J.P. ; Zabielski, M.A. ; Schmaltz, F.L. ; Brownlee, G.G. ; Bussey, L.A. ; Marshall, K. ; Borralho, T. ; Nagata, L.P., "DNA vaccination against respiratory influenza virus infection", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20010321), vol. 19, no. 17-19, ISSN 0264-410X, pages 2461 - 2467, XP027349961 | - |
| OPPOSITION | - Ingmar Hoerr; Reinhard Obst; Hans‐Georg Rammensee; Günther Jung, "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20000830), vol. 30, no. 1, doi:10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#, ISSN 0014-2980, pages 1 - 7, XP071219953 | |
| OPPOSITION | - Shayne Cox, Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043 | |
| OPPOSITION | - Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043 | |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome- entrapped mRNA", Eur. J. Immunol., (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", Eur. J. Immunol, (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - MARTINON F., ET AL., "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA.", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930101), vol. 23., doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722., XP000618955 | |
| OPPOSITION | - LI et al., "Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery", Journal of Gene Medicine, (20050000), vol. 7, doi:10.1002/JGM.634, pages 67 - 79, XP008126013 | |
| OPPOSITION | - PASCOLO S., "Vaccination with messenger RNA (mRNA", Handb Exp Pharmacol, (20080000), doi:10.1007/978-3-540-72167-3_11, pages 221 - 35, XP001538300 | |
| OPPOSITION | - HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer Immunol Immunother, (20060600), vol. 55, no. 6, doi:10.1007/s00262-005-0064-z, pages 672 - 83, XP019333249 | |
| OPPOSITION | - JEFFS et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (20050000), vol. 22, doi:10.1007/s11095-004-1873-z, pages 362 - 372, XP019370801 | |
| OPPOSITION | - JEFFS et al., "A Scalable, Extrustion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372, XP002422317 | |
| OPPOSITION | - Lloyd B. Jeffs et al, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801 | |
| OPPOSITION | - KLIBANOV A L, ET AL., "AMPHIPATHIC POLYETHYLENEGLYCOLS EFFECTIVELY PROLONG THE CIRCULATION TIME OF LIPOSOMES", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (19900701), vol. 268, no. 01, doi:10.1016/0014-5793(90)81016-H, ISSN 0014-5793, pages 235 - 237, XP001073450 | |
| OPPOSITION | - WILSON et al., "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes", Cell, (19790000), vol. 17, doi:10.1016/0092-8674(79)90296-4, pages 77 - 84, XP023910555 | |
| OPPOSITION | - ZHOU X., ET AL., "SELF-REPLICATING SEMLIKI FOREST VIRUS RNA AS RECOMBINANT VACCINE.", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19940101), vol. 12., no. 16., doi:10.1016/0264-410X(94)90074-4, ISSN 0264-410X, pages 1510 - 1514., XP002021790 | |
| OPPOSITION | - Minnaert An-Katrien et al, "Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20210726), vol. 176, doi:10.1016/j.addr.2021.113900, ISSN 0169-409X, XP086773295 | |
| OPPOSITION | - Adriana O. Santos et al, "Design of peptide-targeted liposomes containing nucleic acids", Biochimica et Biophysica Acta, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100301), vol. 1798, no. 3, doi:10.1016/J.BBAMEM.2009.12.001, ISSN 0005-2736, pages 433 - 441, XP002665487 | |
| OPPOSITION | - YAMAMOTO et al., "Current prospects for mRNA gene delivery", Eur J Pharm Biopharm, (20090300), vol. 71, no. 3, doi:10.1016/j.ejpb.2008.09.016, pages 484 - 9, XP025992169 | |
| OPPOSITION | - KIM et al., "Enhanced siRNA delivery using cationic liposomes with new polyarginine- conjugated PEG-lipid", International Journal of Pharmaceutics, (20100000), vol. 392, pages 141 - 147, XP027044515 | |
| OPPOSITION | - Schoenmaker Linde et al, "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20210501), vol. 601, doi:10.1016/j.ijpharm.2021.120586, ISSN 0378-5173, page 120586, XP055828800 | |
| OPPOSITION | - HEYES et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Controlled Release, (20050000), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 | |
| OPPOSITION | - HEYES et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Contr. Release, (20050000), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 | |
| OPPOSITION | - Heyes, J. et al, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20051003), vol. 107, no. 2, doi:10.1016/j.jconrel.2005.06.014, ISSN 0168-3659, pages 276 - 287, XP005076220 | |
| OPPOSITION | - OBATA et al., "Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo", J. Controlled Release, vol. 142, doi:10.1016/j.jconrel.2009.10.023, (20091025), pages 267 - 276, XP026905290 | |
| OPPOSITION | - Wang, D. Christopher, M.E. Nagata, L.P. Zabielski, M.A. Li, H. Wong, J.P. Samuel, J., "Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses", Journal of clinical virology, ELSEVIER, AMSTERDAM, NL, NL , (20041201), vol. 31, doi:10.1016/j.jcv.2004.09.013, ISSN 1386-6532, pages 99 - 106, XP004660136 | |
| OPPOSITION | - Hassett Kimberly J. et al, "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Molecular Therapy-Nucleic Acids, Cell Press, US, US , (20190415), vol. 15, doi:10.1016/j.omtn.2019.01.013, ISSN 2162-2531, pages 1 - 11, XP055815007 | |
| OPPOSITION | - Geall Andrew J. et al, "RNA: The new revolution in nucleic acid vaccines", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US , (19000101), vol. 25, no. 2, doi:10.1016/j.smim.2013.05.001, ISSN 1044-5323, pages 152 - 159, XP028694558 | |
| OPPOSITION | - Jeffrey B. Ulmer et al, "RNA-based vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120418), vol. 30, no. 30, doi:10.1016/j.vaccine.2012.04.060, ISSN 0264-410X, pages 4414 - 4418, XP028520925 | |
| OPPOSITION | - Chu Laurence; McPhee Roderick; Huang Wenmei; Bennett Hamilton; Pajon Rolando; Nestorova Biliana; Leav Brett, "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20210209), vol. 39, no. 20, doi:10.1016/j.vaccine.2021.02.007, ISSN 0264-410X, pages 2791 - 2799, XP086553609 | |
| OPPOSITION | - Saxena, S. ; Sonwane, A.A. ; Dahiya, S.S. ; Patel, C.L. ; Saini, M. ; Rai, A. ; Gupta, P.K., "Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein", VETERINARY MICROBIOLOGY, Elsevier BV, NL, NL , (20090414), vol. 136, no. 1-2, doi:10.1016/j.vetmic.2008.10.030, ISSN 0378-1135, pages 36 - 44, XP026071306 | |
| OPPOSITION | - Szabó Gábor Tamás, Mahiny Azita Josefine, Vlatkovic Irena, "COVID-19 mRNA vaccines: Platforms and current developments", Molecular Therapy, Elsevier Inc., US, US , (20220501), vol. 30, no. 5, doi:10.1016/j.ymthe.2022.02.016, ISSN 1525-0016, pages 1850 - 1868, XP093045424 | |
| OPPOSITION | - FURUICHI et al., "Viral and Cellular mRNA Capping: Past and Prospects", Advances in Virus Research, (20000000), vol. 55, doi:10.1016/S0065-3527(00)55003-9, pages 135 - 184, XP009124440 | |
| OPPOSITION | - FURUICHI et al., "Viral and cellular mRNA capping: past and prospects", Advances in Virus Research, (20000000), vol. 55, pages 135 - 182, XP009124440 | |
| OPPOSITION | - FURUICHI et al., "Viral and cellular mRNA capping: past and prospects", Adv Virus Res, (20000000), vol. 55, doi:10.1016/S0065-3527(00)55003-9, pages 135 - 84, XP009124440 | |
| OPPOSITION | - Furuichi Y; Shatkin A J, "Viral and cellular mRNA capping: past and prospects", Advances in Virus Research, Academic Press, US, US , (20000101), vol. 55, doi:10.1016/S0065-3527(00)55003-9, ISSN 0065-3527, pages 135 - 184, XP009124440 | |
| OPPOSITION | - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556 | |
| OPPOSITION | - Tracy S. Zimmermann, Amy C. H. Lee, Akin Akinc, Birgit Bramlage, David Bumcrot, Matthew N. Fedoruk, Jens Harborth, James A. Heyes, Lloyd B. Jeffs, Matthias John, Adam D. Judge, Kieu Lam, Kevin McClintock, Lubomir V. Nechev, Lorne R. Palmer, Timothy Racie, Ingo Röhl, Stephan Seiffert, Sumi Shanmugam, Vandana Sood, Jürgen Soutschek, Ivanka Toudjarska, Amanda J. Wheat, Ed Yaworski, Ian MacLachlan, "RNAi-mediated gene silencing in non-human primates; Including: Supplementary information: Supplementary Methods & Supplementary Figures and Table", NATURE, Springer Nature Publishing AG, LONDON, LONDON , (20060504), vol. 441, no. 7089, doi:10.1038/nature04688, ISSN 1476-4687, pages 111 - 114, 1-7, 1-7, XP002412249 | |
| OPPOSITION | - DAFFIS et al., "2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members", Nature, (20100000), vol. 468, doi:10.1038/nature09489, pages 452 - 456, XP037065800 | |
| OPPOSITION | - Benjamin Petsch et al, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, Gale Group Inc., (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 10870156, pages 1210 - 1216, XP055051005 | |
| OPPOSITION | - Ugur Sahin et al, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, Nature Pub. Group, vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 14741776, pages 759 - 780, XP055159205 | |
| OPPOSITION | - Akinc Akin et al, "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nature Nanotechnology, Nature Pub. Group, Inc., London, London , (20191201), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, ISSN 1748-3387, pages 1084 - 1087, XP036953174 | |
| OPPOSITION | - Hirano T; Fujimoto J; Ueki T; Yamamoto H; Iwasaki T; Morisita R; Sawa Y; Kaneda Y; Takahashi H; Okamoto E, "Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome", Gene Therapy, Nature Publishing Group, London, GB, GB , (19980401), vol. 5, no. 4, doi:10.1038/sj.gt.3300617, ISSN 0969-7128, pages 459 - 464, XP037773612 | |
| OPPOSITION | - Wheeler J J; Palmer L; Ossanlou M; MacLachlan I; Graham R W; Zhang Y P; Hope M J; Scherrer P; Cullis P R, "Stabilized plasmid-lipid particles: construction and characterization", Gene Therapy, Nature Publishing Group, London, GB, GB , (19990201), vol. 6, no. 2, doi:10.1038/sj.gt.3300821, ISSN 0969-7128, pages 271 - 281, XP037770556 | |
| OPPOSITION | - COWLING, "Regulation of mRNA cap methylation", Biochem. J., (20100115), vol. 425, doi:10.1042/BJ20091352, pages 295 - 302, XP055980156 | |
| OPPOSITION | - DZAU V J, ET AL., "FUSIGENIC VIRAL LIPOSOME FOR GENE THERAPY IN CARDIOVASCULAR DISEASES", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (19961001), vol. 93, no. 21, doi:10.1073/pnas.93.21.11421, ISSN 0027-8424, pages 11421 - 11425, XP001188950 | |
| OPPOSITION | - POLO et al., "Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors", Proc. Natl. Aca. Sci, (19990400), vol. 96, doi:10.1073/pnas.96.8.4598, pages 4598 - 4603, XP002139370 | |
| OPPOSITION | - BELANGER et al., "Characterization of hMTr1, a Human Cap12'-O-Ribose Methyltransferase", KJ. Biol. Chem., (20100000), vol. 285, doi:10.1074/jbc.M110.155283, pages 33037 - 33044, XP055443707 | |
| OPPOSITION | - Norbert Pardi, Et Al., "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20180604), vol. 215, no. 6, doi:10.1084/jem.20171450, ISSN 0022-1007, pages 1571 - 1588, XP055545604 | |
| OPPOSITION | - FLEETON et al., "Self-replicative RNA vaccines elicit protection against influenza A virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus", Journal of Infectious Diseases, (20010000), vol. 183, doi:10.1086/319857, pages 1395 - 8, XP002224503 | |
| OPPOSITION | - W-Z Zhou et al, "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (19991101), vol. 10, no. 16, ISSN 1043-0342, pages 2719 - 2724, XP002660042 | |
| OPPOSITION | - Y Saeki, N Matsumoto, Y Nakano, M Mori, K Awai, Y Kaneda, "Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (19971120), vol. 8, no. 17, doi:10.1089/hum.1997.8.17-2133 , ISSN 1043-0342, pages 2133 - 2141, XP000992958 | |
| OPPOSITION | - ISHIKAWA et al., "Preparation of eukaryotic mRNA having differently methylated adenosine at the 5'-terminus and the effect of the methyl group in translation", Nucleic Acids Symposium Series, (20090000), doi:10.1093/nass/nrp065, pages 129 - 130, XP055331388 | |
| OPPOSITION | - FECHTER P, BROWNLEE G G, "Recognition of mRNA cap structures by viral and cellular proteins", Journal of General Virology, Society for General Microbiology, (20050101), vol. 86, doi:10.1099/VIR.0.80755-0, ISSN 0022-1317, pages 1239 - 1249, XP002516933 | |
| OPPOSITION | - Ramos Da Silva Jamile, Bitencourt Rodrigues Karine, Formoso Pelegrin Guilherme, Silva Sales Natiely, Muramatsu Hiromi, De Oliveira Silva Mariângela, Porchia Bruna F.M.M., Moreno Ana, Aps Luana, Venceslau-Carvalho Aléxia Adrianne, Tombácz István, Fotoran Wesley Luzetti, Karikó Katalin, Lin Paulo J.C., Tam Ying K., De Oliveira Diniz Mariana, Pardi Norbert, De Souza Ferreira Luís Carlos, "Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice", SCIENCE TRANSLATIONAL MEDICINE, American Association for the Advancement of Science (A A A S), US, US , (20230308), vol. 15, no. 686, doi:10.1126/scitranslmed.abn3464, ISSN 1946-6242, pages eabn3464 - 18, XP093243379 | |
| OPPOSITION | - BANERJEE, "5'-Terminal Cap Structure in Eucaryotic Messenger Ribonucleic Acids", Microbiol. Rev., (19800000), vol. 44, pages 175 - 205, XP055897139 | |
| OPPOSITION | - Banerjee Amiya K, "5'-Terminal Cap Structure in Eucaryotic Messenger Ribonucleic Acids", Microbiological Reviews, (19800601), vol. 44, no. 2, pages 175 - 205, XP055897139 | |
| OPPOSITION | - Kawano, Et Al., "Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin In Vitro", J. Drug. Delivery, doi:10.1155/2011/160967, (20110101), pages 1 - 6, J. Drug. Delivery, (20190925), XP055626067 | |
| OPPOSITION | - SONOKE et al., "Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes", Cancer Research, (20080000), vol. 68, doi:10.1158/0008-5472.CAN-08-0127, pages 8843 - 8851, XP055046252 | |
| OPPOSITION | - S. Sonoke et al, "Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes", Cancer research, American Association for Cancer Research, (20081101), vol. 68, no. 21, doi:10.1158/0008-5472.CAN-08-0127, ISSN 00085472, pages 8843 - 8851, XP055046252 | |
| OPPOSITION | - KOWALSKA et al., "Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS", RNA, (20080000), vol. 14, doi:10.1261/rna.990208, pages 1119 - 1131, XP002554206 | |
| OPPOSITION | - Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), vol. 127, ISSN 1543-1894, pages 23 - 40, XP009117840 | |
| OPPOSITION | - PASCOLO S., "Messenger RNA-based vaccines", Expert Opin Biol Ther, (20040800), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, pages 1285 - 94, XP009095328 | |
| OPPOSITION | - Deering Raquel P. et al, "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.", Expert opinion on drug delivery, Informa Healthcare, UK, UK , (20140601), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, ISSN 1744-7593, pages 885 - 899, XP009183535 | |
| OPPOSITION | - Morais Pedro et al, "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines", Frontiers in Cell and Developmental Biology, vol. 9, doi:10.3389/fcell.2021.789427, XP055885272 | |
| OPPOSITION | - Karl-Josef Kallen et al, "A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines", Human vaccines & immunotherapeutics, (20131001), vol. 9, no. 10, doi:10.4161/hv.25181, ISSN 21645515, pages 2263 - 2276, XP055126357 | |
| OPPOSITION | - SCHLAKE T. et al, "Developing mRNA-vaccine technologies", RNA BIOLOGY, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, pages 1319 - 1330, XP002743467 | |
| SEARCH | - MOCKEY M ET AL, "mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes", CANCER GENE THERAPY, (200709), vol. 14, no. 9, ISSN 0929-1903, pages 802 - 814, XP055007324 [I] 1-12 * page 804, column l, paragraph 4 * | |
